Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden mice
RNA-seq (gene expression) · mouse · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 24 samples: 24 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden miceFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE255321_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1074673 and SRA study SRP488877. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 24 sample titles: 24 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8069055 Subj_32,liver,HFD33w_Ctr-Ab12w
- GSM8069056 Subj_33,liver,HFD33w_Ctr-Ab12w
- GSM8069057 Subj_34,liver,HFD33w_Ctr-Ab12w
- GSM8069058 Subj_35,liver,HFD33w_Ctr-Ab12w
- GSM8069059 Subj_36,liver,HFD33w_Ctr-Ab12w
- GSM8069060 Subj_37,liver,HFD33w_Ctr-Ab12w
- GSM8069061 Subj_38,liver,HFD33w_Ctr-Ab12w
- GSM8069062 Subj_40,liver,HFD33w_Ctr-Ab12w
- GSM8069063 Subj_41,liver,HFD33w_Ctr-Ab12w
- GSM8069064 Subj_42,liver,HFD33w_Ctr-Ab12w
- GSM8069065 Subj_43,liver,HFD33w_Ctr-Ab12w
- GSM8069066 Subj_45,liver,HFD33w_Ctr-Ab12w
- GSM8069067 Subj_46,liver,HFD33w_bFKB1-Ab12w
- GSM8069068 Subj_48,liver,HFD33w_bFKB1-Ab12w
- GSM8069069 Subj_49,liver,HFD33w_bFKB1-Ab12w
- GSM8069070 Subj_50,liver,HFD33w_bFKB1-Ab12w
- GSM8069071 Subj_52,liver,HFD33w_bFKB1-Ab12w
- GSM8069072 Subj_54,liver,HFD33w_bFKB1-Ab12w
- GSM8069073 Subj_55,liver,HFD33w_bFKB1-Ab12w
- GSM8069074 Subj_56,liver,HFD33w_bFKB1-Ab12w
- GSM8069075 Subj_57,liver,HFD33w_bFKB1-Ab12w
- GSM8069076 Subj_58,liver,HFD33w_bFKB1-Ab12w
- GSM8069077 Subj_59,liver,HFD33w_bFKB1-Ab12w
- GSM8069078 Subj_60,liver,HFD33w_bFKB1-Ab12w
- GSE295343 FGF21 reverses MASH through coordinated actions on the CNS and liver 12 samples shares fgf21, mash
- GSE301751 Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse Model (study 7/9) 53 samples shares mash, therapeutic
- GSE310507 Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse Model (study 6) 24 samples shares mash, therapeutic
- GSE304787 Therapeutic targeting of lipidated amino acid deficiency ameliorates MASH via a PPARα/CCL2 axis 14 samples shares mash, therapeutic
- GSE297831 Imidazole propionate is an early biomarker and therapeutic target for atherosclerosis [bulk RNA-seq] 27 samples shares atherosclerosis, therapeutic
- GSE210460 Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice 24 samples shares atherosclerosis, ldlr
- GSE269426 Integrated multi-omic high-throughput strategies across-species identified potential key diagnostic, prognostic, and therapeutic targets for atherosclerosis under high glucose conditions 16 samples shares atherosclerosis, therapeutic
- GSE298492 Macrophage-derived KIF13B acts as a potential therapeutic target in atherosclerosis by enhancing MERTK-mediated efferocytosis [RNA-Seq] 12 samples shares atherosclerosis, therapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.